Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2013

View Archived Issues

Charleston Laboratories completes phase III trial of CL-108 at the midway point

Chugai Pharmaceutical presents highlights of third quarter 2013

Mayo Clinic and Mayo Medical Laboratories to offer bioTheranostics' CancerTYPE ID test

AstraZeneca begins phase III benralizumab program in severe asthma

Lurbinectedin shows promise in phase Ib lung cancer trials

Numab reacquires ND-003 from Sucampo Pharmaceuticals

Gates Foundation enters Vaccine Discovery Partnerships with GSK and Sanofi Pasteur

Hanmi's HM-61713 effective in phase I NSCLC trial

Merck Serono expands two collaborations

IncellDx and Bristol-Myers to develop assay for companion diagnostic test

First phase II results reported for MLN-8237 in SCLC

Xoma reports results from two phase II studies in proof-of-concept program for gevokizumab

Mitsubishi Tanabe provides update on product development in second quarter of 2013

Targeting siglec-15 with an antibody reduces bone loss in ovariectomized rats

Anti-sclerostin monoclonal antibody shows promise in phase IIa hypophosphatasia trial

Model used to predict increase in bone mineral density with DS-9194b

Integrated Diagnostics presents new lung blood test

Phase II trial of Cornerstone Pharmaceuticals' CPI-613 in pancreatic cancer begins

Novartis files petition with the FDA regarding naming policy for biosimilars

Ariad Pharmaceuticals temporarily suspends sales of ponatinib at request of FDA

Baxter submits MAA to EMA for Rixubis

Synergy Pharmaceuticals starts phase II study of SP-333 for OIC

SymBio and Eisai discontinue Japanese phase II trial of Treakisym

Glenmark Pharmaceuticals patents new ITK inhibitors

Japanese researchers disclose new alpha7 receptor positive allosteric modulators

New GTPas KRas inhibitors for cancer presented by the University of California

FDA approves Gazyva for previously untreated chronic lymphocytic leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...